<li>acebutolol<p>losartan and acebutolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>acebutolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>aceclofenac<p>losartan and aceclofenac both increase  serum potassium. Use Caution/Monitor.</p></li><li>acemetacin<p>losartan and acemetacin both increase  serum potassium. Use Caution/Monitor.</p></li><li>albiglutide<p>losartan increases effects of albiglutide by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>aldesleukin<p>aldesleukin increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amifostine<p>amifostine increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amiloride<p>losartan and amiloride both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.<span><br><br></span>amiodarone decreases effects of losartan by decreasing metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>amphetamine<p>amphetamine decreases effects of losartan by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>aspirin<p>losartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>aspirin rectal<p>losartan and aspirin rectal both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan and aspirin/citric acid/sodium bicarbonate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>losartan, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>atenolol<p>losartan and atenolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>atenolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>avanafil<p>avanafil increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>axitinib<p>losartan increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bambuterol<p>losartan increases and bambuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bendroflumethiazide<p>losartan increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>betaxolol<p>losartan and betaxolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>betaxolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>bisoprolol<p>losartan and bisoprolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>bisoprolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>bosentan<p>bosentan will decrease the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>brimonidine<p>brimonidine increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>bumetanide<p>losartan increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>canagliflozin<p>losartan and canagliflozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>candesartan<p>candesartan and losartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>carbenoxolone<p>losartan increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carvedilol<p>losartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>celecoxib<p>losartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>celiprolol<p>losartan and celiprolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celiprolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>chlorothiazide<p>losartan increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorthalidone<p>losartan increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>cholic acid<p>losartan increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin.</p></li><li>choline magnesium trisalicylate<p>losartan and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>choline magnesium trisalicylate decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, choline magnesium trisalicylate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>crofelemer<p>crofelemer increases levels of losartan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclopenthiazide<p>losartan increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of losartan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>dalteparin<p>dalteparin increases toxicity of losartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>diclofenac<p>losartan and diclofenac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>diclofenac decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, diclofenac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>diflunisal<p>losartan and diflunisal both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>diflunisal decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, diflunisal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>digoxin<p>losartan and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>divalproex sodium<p>divalproex sodium will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>dopexamine<p>losartan increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>drospirenone<p>losartan and drospirenone both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>efavirenz<p>efavirenz will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of losartan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of losartan by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>enoxaparin<p>enoxaparin increases toxicity of losartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ephedrine (pulmonary)<p>losartan increases and ephedrine (pulmonary) decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>eplerenone<p>losartan, eplerenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>eprosartan<p>eprosartan and losartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>esmolol<p>losartan and esmolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>esmolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>ethacrynic acid<p>losartan increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>etodolac<p>losartan and etodolac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>etodolac decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, etodolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>etoricoxib<p>losartan and etoricoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>etravirine<p>etravirine will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>exenatide injectable solution<p>losartan increases effects of exenatide injectable solution by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>exenatide injectable suspension<p>losartan increases effects of exenatide injectable suspension by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>felbamate<p>felbamate will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>fenbufen<p>losartan and fenbufen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fenoprofen<p>losartan and fenoprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>fenoprofen decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, fenoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>flibanserin<p>losartan will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>flurbiprofen<p>losartan and flurbiprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>flurbiprofen decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, flurbiprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>furosemide<p>losartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>gentamicin<p>losartan increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>heparin<p>heparin increases toxicity of losartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>hydrochlorothiazide<p>losartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ibuprofen<p>losartan and ibuprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ibuprofen decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, ibuprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>iloperidone<p>iloperidone increases levels of losartan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>imatinib<p>imatinib will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>indapamide<p>losartan increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>indomethacin<p>losartan and indomethacin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>indomethacin decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, indomethacin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>insulin degludec<p>losartan, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin degludec/insulin aspart<p>losartan, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin inhaled<p>losartan, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>irbesartan<p>irbesartan and losartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>ketoprofen<p>losartan and ketoprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketoprofen decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, ketoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac<p>losartan and ketorolac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketorolac decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, ketorolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac intranasal<p>losartan and ketorolac intranasal both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketorolac intranasal decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, ketorolac intranasal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>labetalol<p>losartan and labetalol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>labetalol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>leflunomide<p>leflunomide will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.<span><br><br></span>leflunomide decreases effects of losartan by decreasing metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>levodopa<p>levodopa increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>liraglutide<p>losartan increases effects of liraglutide by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>lomitapide<p>losartan increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>lornoxicam<p>losartan and lornoxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, losartan. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .</p></li><li>lurasidone<p>lurasidone increases effects of losartan by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>maitake<p>maitake increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>maraviroc<p>maraviroc, losartan.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.</p></li><li>meclofenamate<p>meclofenamate decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan and meclofenamate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>losartan, meclofenamate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mefenamic acid<p>losartan and mefenamic acid both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>mefenamic acid decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, mefenamic acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>meloxicam<p>losartan and meloxicam both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>meloxicam decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, meloxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>methyclothiazide<p>losartan increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>metolazone<p>losartan increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metoprolol<p>losartan and metoprolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>metoprolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.<span><br><br></span>miconazole vaginal decreases effects of losartan by decreasing metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>mipomersen<p>mipomersen, losartan.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mitotane<p>mitotane decreases levels of losartan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>nabumetone<p>losartan and nabumetone both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nabumetone decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, nabumetone.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>nadolol<p>losartan and nadolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nadolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>naproxen<p>losartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>nateglinide<p>nateglinide will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>nebivolol<p>losartan and nebivolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nebivolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of losartan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, losartan.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>olmesartan<p>losartan and olmesartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of losartan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Decrease dose of angiotensin receptor  blockers and monitor patients for signs and symptoms of hypotension and/or worsening renal function; if such events occur, consider further dose reduction of angiotensin receptor blocker or switching to alternative to angiotensin receptor blocker </p></li><li>omeprazole<p>omeprazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>oxaprozin<p>losartan and oxaprozin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>oxaprozin decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, oxaprozin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>paclitaxel<p>losartan will increase the level or effect of paclitaxel by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>paclitaxel protein bound<p>losartan will increase the level or effect of paclitaxel protein bound by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>parecoxib<p>losartan and parecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of losartan by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. .</p></li><li>penbutolol<p>losartan and penbutolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>penbutolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>pindolol<p>losartan and pindolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>pindolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>piroxicam<p>losartan and piroxicam both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>piroxicam decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, piroxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>potassium acid phosphate<p>losartan and potassium acid phosphate both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium chloride<p>losartan and potassium chloride both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium citrate<p>losartan and potassium citrate both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium citrate/citric acid<p>losartan and potassium citrate/citric acid both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>propranolol<p>losartan and propranolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>propranolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>rifampin<p>rifampin will decrease the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>sacubitril/valsartan<p>losartan and sacubitril/valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>salicylates (non-asa)<p>losartan and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor.</p></li><li>salsalate<p>losartan and salsalate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>salsalate decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, salsalate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>sotalol<p>losartan and sotalol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sotalol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>spironolactone<p>losartan and spironolactone both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>sulfamethoxazole<p>sulfamethoxazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>sulfasalazine<p>losartan and sulfasalazine both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sulfasalazine decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, sulfasalazine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>sulindac<p>losartan and sulindac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sulindac decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, sulindac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>tadalafil<p>tadalafil increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>telmisartan<p>losartan and telmisartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>terbutaline<p>losartan increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>timolol<p>losartan and timolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>timolol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>tinzaparin<p>tinzaparin increases toxicity of losartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>tizanidine<p>tizanidine increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>tolfenamic acid<p>losartan and tolfenamic acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolmetin<p>losartan and tolmetin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>tolmetin decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, tolmetin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>tolvaptan<p>losartan and tolvaptan both increase  serum potassium. Use Caution/Monitor.</p></li><li>torsemide<p>losartan increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>treprostinil<p>treprostinil increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>triamterene<p>losartan and triamterene both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>trimethoprim<p>trimethoprim and losartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>valsartan<p>losartan and valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.<span><br><br></span>voriconazole decreases effects of losartan by decreasing metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>xipamide<p>xipamide increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.<span><br><br></span>zafirlukast decreases effects of losartan by decreasing metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li>